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Abstract
Patterns of invasive fungal infections are changing in many ways. Although yeast infections appear to have reached a stable incidence,
the number of infections as a result of Aspergillus species appears to be increasing. Especially for mould infection, the diagnosis remains
difﬁcult and the detection and identiﬁcation of clinically relevant isolates to the species level requires new validated techniques. Diagnos-
tic tests are becoming more accurate, with biological markers such as PCR, galactomannan and 1,3 b-D-glucan undergoing clinical valida-
tion. This is of importance because an early diagnosis is associated with increased survival. Correct diagnosis and in vitro susceptibility
testing are becoming imperative for guidance of therapy in the context of changing epidemiology and the emergence of acquired resis-
tance to antifungal drugs, as is insight into host factors that increase susceptibility to invasive mould infection and into the risks associ-
ated with new treatment modalities of underlying diseases. Despite improvements in the survival rates of patients with invasive fungal
infection in recent years, continued research is required to meet the challenges associated with changes in epidemiology and resistance
development.
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Introduction
Invasive yeast and mould infections in immunocompro-
mised patients (i.e. haematological, solid organ transplant
or intensive care unit patients) have consistently shown a
lower incidence in comparison with bacterial infections
during the past decades [1,2]. Nevertheless, their burden
is immense because of the high morbidity and mortality
rates in infected patients. Although invasive yeast infec-
tions, primarily invasive Candida albicans infections, have
shown a slight decrease in North American centres during
the past decade, the incidence of non-albicans Candida
infections and those caused by rare yeasts is increasing
relatively [1]. Mould infections, especially as a result of
Aspergillus species, are still increasing [3,4]. Better diagnos-
tic tests and procedures, such as galactomannan detection
and high-resolution computed tomography scans, together
with the availability of more potent drugs have improved
the prognosis for patients with invasive fungal diseases [3],
yet the mortality rate has not decreased signiﬁcantly [1].
However, improvements in the management of patients
with invasive fungal infections come with a cost. Opportu-
nistic fungi, other than Aspergillus and Candida, have
emerged, with ensuing difﬁculties in their diagnosis and
treatment. Acquired resistance to azoles and echinocandins
has been reported, which also complicates the manage-
ment of patients with invasive fungal diseases. With highly
sensitive diagnostic assays, such as PCR, it may be very
difﬁcult to prove the presence of an invasive fungal
infection because the detection of circulating fungal DNA
is not necessarily associated with clinical manifestations of
the fungal disease. Diagnostic tools can be adequately used
only if the treating physician is aware of the propensity of
patients to acquire a fungal infection. With the changing
treatment modalities, new risk groups may emerge, which
requires continuous awareness and education. For exam-
ple, the recognition of patients with increased susceptibility
to fungal infections as a result of inherited immunity
anomalies, such as impaired NADPH-oxidase activity [5,6],
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disturbed interleukin (IL)-10 or tumour necrosis factor
(TNF)a production [7–9] and genetic polymorphisms in
Toll-like receptors that result in defective production of
inﬂammatory cytokines [10], is of importance. In addition,
biological factors such as iron overload and age have also
been shown to increase the risk of developing invasive
fungal infections [11]. Historically recognized risk factors,
such as corticosteroid use and neutropenia, along with
myeloablative treatment regimens, further augment the
aforementioned risk factors. However, even novel treat-
ment modalities that allow less intensive conditioning,
remain associated with invasive fungal infections [12]. In
this review, we aim to discuss the changing factors related
to the fungus and the host, together with their impact on
patient management.
The Fungus
The taxonomy of several fungi has changed in recent years
because of an approach referred to as polyphasic taxonomy,
which is based on analysis of macro- and micromorphology,
extrolite proﬁles and b-tubulin, calmodulin, internally tran-
scribed space (ITS) and actin gene sequences of the isolates
[13]. The new taxonomy has a major impact on the number
of species, especially within the genus Aspergillus. Within the
medically important sections Fumigati, Nigri and Nidulanti,
numerous new species were identiﬁed. For example, the
section Fumigati (teleomorph Neosartorya) now contains 30
species that cannot be readily differentiated by macroscopic
and microscopic features alone [13]. Cryptogenic species
include Aspergillus lentulus, Aspergillus pseudoﬁscheri and
Aspergillus udagawae, and some of these can be differentiated
from Aspergillus fumigatus by their inability to grow at 48C.
Therefore, sequence-based analysis is required to correctly
identify isolates to the species level. Because ITS sequencing,
which is commonly performed in clinical microbiology
laboratories, does not discriminate among the cryptogenic
species, a major change would be required to correctly
identify the species. The clinical relevance of molecular iden-
tiﬁcation to the species level remains unclear because the
ability of most cryptogenic species to cause invasive fungal
disease is presently unknown [14]. It can be expected that,
in due course, commercial DNA-based assays will become
available for molecular strain identiﬁcation. However,
because the cryptogenic species differ in their susceptibility
to antifungal agents compared to A. fumigatus, it might be
appropriate, in the meantime, to determine the in vitro
susceptibility of clinically relevant isolates to guide antifungal
therapy.
Diagnostic Tools for Detecting Fungi
Causing Infections
For all those involved in the care of patients with invasive
mould diseases, the availability of validated, reliable and rapid
diagnostic methods as well as effective treatment options
comprise important issues [15]. With an adequate diagnostic
armamentarium, we can limit the morbidity and mortality as
a result of invasive mould infections. The importance of
avoiding any delay in the initiation of adequate antifungal
therapy on the outcome of patients with invasive fungal dis-
eases has become evident both in invasive Candida infections
[16] and in invasive aspergillosis [17]. Non-culture-based
assays have been increasingly used to diagnose infections ear-
lier, and the detection of galactomannan has become valuable
despite the reported heterogeneity in the performance of
the test [18]. Overall, galactomannan detection in serum is
most useful in neutropenic patients with a haematological
malignancy who are not exposed to antifungal prophylaxis
active against moulds [19,20]. In this setting, prospective
monitoring is sometimes used, which appears to be a feasible
strategy, provided that the prevalence of invasive aspergillosis
is high [21]. An important issue is whether the use of biolog-
ical markers, in combination with improved imaging tech-
niques, as a management strategy will help us to better
identify those patients who require antifungal therapy. Stud-
ies that compare an empirical treatment strategy with such a
diagnostic driven strategy indicate that, with a diagnostic dri-
ven strategy, the use of antifungal agents can be reduced
without compromising the prognosis for the patient [22,23].
However, additional conﬁrmative studies are warranted
before such a diagnostic driven approach can become com-
mon practise. Indeed, different strategies probably need to
be followed in the various treatment phases because the risk
of invasive fungal infections differs during each phase.
In non-neutropenic patients, the value of the detection of
circulating galactomannan is limited because of low sensitivity.
In these patients, galactomannan detection in BAL-ﬂuid
might be more appropriate to diagnose invasive pulmonary
aspergillosis [24].
Another antigen that can be detected is 1,3-b-D-glucan
(BG), which is a cell wall component of many fungi, including
Candida and Aspergillus. The detection of BG was included as
mycological evidence of invasive fungal infection in the
recently published revised deﬁnitions of the European Orga-
nization for Research and Treatment of Cancer/Invasive Fun-
gal Infections Cooperative Group and the National Institute
of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) Consensus Group [25]. Although the clinical
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experience with BG detection in patients with invasive fungal
infection is still limited, a possible role in the management of
patients at risk of invasive Candida infection in the intensive
care unit is currently being investigated [26].
Although the ﬁrst PCR for the detection of Aspergillus was
reported in the early 1990s, this technique is still considered
as experimental more than 15 years later. Aspergillus PCR
appears to have some very promising beneﬁts and may com-
plement properties of other biological tests, such as galacto-
mannan antigen detection. Aspergillus DNA can be detected
very early in patients with invasive aspergillosis, frequently in
a phase devoid of clinical signs and symptoms of invasive fun-
gal infection [27]. Also, exposure to antifungal drugs might
improve the sensitivity of the assay as opposed to galacto-
mannan detection, where the reverse is the case [28].
Although a clinically validated commercial format is still lack-
ing, the platforms are becoming more automated and the
extraction methods and targets are becoming commercially
available. An international initiative that involves many inves-
tigators aims to devise a standard for Aspergillus PCR, which
would subsequently allow clinical validation [29]. The stan-
dard for PCR should be available before the next revision of
the EORTC/MSG deﬁnitions, so that it may be included as
mycological evidence.
Acquired Resistance
Although intrinsic resistance is known in the case of certain
drug–Aspergillus species combinations, acquired resistance
remains uncommon. Resistance has been reported to
emerge in patients with an aspergilloma or with chronic
aspergillosis who have been treated with itraconazole [30].
Resistance is most commonly associated with point muta-
tions in the Cyp51A gene and most isolates exhibit a pheno-
type of cross-resistance [31]. In addition, resistance has been
observed to have emerged in patients with acute invasive
aspergillosis in the Netherlands, with 6–12.8% of patients
harbouring a resistant isolate [32]. A. fumigatus isolates resis-
tant to itraconazole and with reduced susceptibility to voric-
onazole and posaconazole were found and, in patients
infected with resistant isolates, azole therapy was unsuccess-
ful [33]. The azole-resistant isolates appear to be as virulent
as wild-type isolates [32], and even cases of azole-resistant
central nervous system aspergillosis were reported that were
very difﬁcult to manage [34]. Because a single highly domi-
nant resistance mechanism was found in the Dutch clinical
isolates, it was suggested that azole resistance might have
developed through exposure to azole fungicides in the envi-
ronment rather than in azole-treated patients [35]. Indeed,
A. fumigatus isolates resistant to medical triazoles were cul-
tured from the hospital indoor environment and from soil
samples and compost. These isolates were found to have
resistance mechanisms identical to those found in the major-
ity of clinical isolates, and genotyping showed clustering of
resistant isolates of clinical and environmental origin [35].
This suggests that patients with azole-resistant aspergillosis
might acquire the isolate from the environment, which is
also the primary route of transmission for azole-susceptible
A. fumigatus. Furthermore, azole-resistant A. fumigatus may
be spreading in the environment,
All of the above complicates the implementation of effec-
tive measures that prevent further dissemination. Although
the clinical efﬁcacy of voriconazole and posaconazole against
azole-resistant aspergillosis remains unclear, the use of these
azoles should be avoided in acute infection until more expe-
rience has been gained.
Elevated MIC values of echinocandins with occasional
treatment failure have been reported for strains of Candida,
but the relation between MIC and clinical response remains
unclear [36]. However, resistance to echinocandin drugs
among clinical isolates was associated with amino acid substi-
tutions in two ‘hot-spot’ regions of Fks1, the major subunit
of glucan synthase [36,37]. The Fks1-mediated resistance
mechanism is conserved in a wide variety of Candida species
and can account for intrinsic reduced susceptibility of certain
species. Fks1 mutations confer resistance in both yeasts and
moulds, and sporadic A. fumigatus isolates have been found
that are resistant to echinocandins. However, in some phe-
notypic caspofungin-resistant isolates, no mutations were
found in the Fks1gene, indicating that other, yet unknown,
mechanisms are present [38,39]. Of note is that caspofungin
(i.e. echinocandins) may play a pivotal role in a possible
synergy between the antifungal drug and the host immune
system [40]. Echinocandins can induce (even at low conce-
trations) morphological changes in hyphae of A. fumigatus,
which, as a concequence, increase glycan b exposure, result-
ing in an increased Dectin-1-mediated inﬂammatory response
by macrophages, as well as in enhancement of the activity of
polymorphonuclear neutrophils (PMNs) [41,42].
Given the limited number of evidence-based treatment
options in invasive candidiasis and invasive aspergillosis
(Table 1), the loss of a class of antifungals, as a result of
acquired resistance, signiﬁcantly complicates patient manage-
ment. In the coming years, priority should be given to moni-
toring of the extent and spread of (azole) resistance in
opportunistic fungi, to the determination of interpretative
breakpoints for all clinically used antifungal agents, and to the
development of antifungal compounds that are active against
new targets.
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Host-Related Factors Predisposing to
Mould Infections
Several well described and established factors have been
deﬁned that predispose patients for invasive mould infec-
tions, such as invasive aspergillosis. Some of them, such as
neutropenia as a result of meyloablative therapy in acute leu-
kaemia or allogeneic haematopoietic stem cell transplantation
(HSCT), are ubiquitous in their consequence of increasing
the risk of mould infections. Although yeast infections are
often acquired through disruption of the integrity of the
mucosal barrier, mould infections are primarily caused by
inhalation of conidia and, consequently, the lungs are fre-
quently the primary site of infection. Yet, the intestine also
has been reported to be a possible site of invasive Aspergillus
infection [43], especially in chronic graft-versus-host disease
(GvHD), or in patients with mucosal barrier injury related to
the conditioning regimen.
Genetic Factors Predisposing to Invasive
Aspergillosis
Germination of conidia is the ﬁrst step in the pathogenesis of
invasive aspergillosis. One of the backbones of the host
defence that may prevent Aspergillus invasion is formed by early
recruitment of PMNs to the site of infection [6]. Together
with alveolar macrophages, their role is essential in exertion of
the NADPH-oxidase activity within PMN aggregates to pre-
vent hyphal proliferation and tissue invasion. Defective oxidant
production within PMN aggregates largely contributes to host
susceptibility to invasive aspergillosis. This can explain why
neutropenia, defective NADPH-oxidase and corticosteroids,
which delay the recruitment of PMNs, are important predis-
posing factors for invasive mould infection [5,6].
In addition, other host-related factors (e.g. the production
of IL-10 and TNFa) have a role in the development of inva-
sive mould infections such as invasive aspergillosis. IL-10 acts
as a major regulatory cytokine of inﬂammatory responses by
controlling the balance between inﬂammatory and humoral
responses [44]. It operates by impairing the antifungal effec-
tor function in phagocytes and the secretion of proinﬂamma-
tory cytokines in macrophages, T-cells, neutrophils and
dendritic cells [44,45]. Single nucleotide polymorphisms in
the IL-10 gene promoter were found to be an independent
predictive factor for the development of invasive aspergillosis
in a study with patients treated by allogeneiec HSCT [8]. In
that study, patients with the ACC haplotype (associated with
decreased IL-10 production) had a nine-fold lower risk of
developing invasive aspergillosis compared to control
patients with unaffected IL-10 production. Among those with
the ATA haplotype (associated with increased IL-10 produc-
tion), a signiﬁcantly higher incidence of invasive aspergillosis
was observed. Because the precise role of IL-10 is currently
not yet fully understood, further studies are required to
determine the deﬁnite value of these observations.
High levels of proinﬂammatory cytokines, such as TNFa
and lymphotoxin a), are required for adequate control of an
invasive fungal infection. Because 60% of the variation in
TNFa production is considered to be genetically determined,
this factor may explain in part the inter-individual differences
in the risk of patients undergoing similar immunosuppressive
treatment regimens to develop invasive fungal infection (i.e.
in addition to factors related to exposure to the fungus). In
HSCT recipients, genetic differences in the TNFa receptor
type 2 promoter have also been shown to have a pivotal role
in host susceptibility to invasive aspergillosis [9]. Another
defect in the innate immunity mechanism can also increase
host susceptibility to invasive mould infection. Toll-like recep-
tors are transmembrane proteins on the surface of immune
cells that interact with several adapter proteins to activate
transcription factors, resulting in the production of inﬂamma-
tory cytokines and activation of the adaptive immunity [10].
Because Aspergillus, once present in the human body, activates
innate immune cells through Toll-like receptors 2 and 4, the
absence or weakness of this signal by epithelial cells of recipi-
ents or phagocytic cells from the stem cell donor can lead to
an increased risk of acquiring invasive aspergillosis. Single
nucleotide polymorphisms in Toll-like receptors 4 haplotype
S4 in unrelated donors of HSCT recipients were associated
with increased host susceptibility to invasive aspergillosis.
Similar observations were reported in a single study investi-
gating the presence of polymorphisms in Toll-like receptors 1
and 6 [46]. Polymorphisms in this area of the innate human
immunity system are also considered to be associated with
an increased risk of invasive yeast infections such as invasive
candidiasis [47]. Another factor that was shown to be associ-
ated with increased susceptibility to invasive aspergillosis is
polymorphism in the plasminogen gene [48].
The number of different host-related genetic factors pre-
disposing to an invasive fungal infection is high and increasing
(Table 2), although their speciﬁc and additive roles are yet
to be fully understood.
Biological Factors
Along with the aforementioned direct host-related factors,
iron overload, which can be acquired during the course of
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treatment of the underlying disease, can lead to increased
host susceptibility to fungal infections. This has been shown
for myeloma patients [11] and for HSCT recipients [49].
The mechanism is considered to act through the increased
availability of iron for fungal proliferation and the negative
effects of iron overload on the antimicrobial functions of
neutrophils, monocytes and natural killer cells. Among other
biological host factors, older age is also increasingly recog-
nized as a risk factor for several serious infections because
this group of elderly patients is demographically becoming
larger. In a multivariable analysis, age was found to be an
independent risk factor for invasive mould infections in
HSCT patients, in contrast to other biological factors such
as acidosis and hyperglycaemia that did not increase the risk
[50].
The trend to manage high-risk patients in the outpatient
setting presents new challenges for the early diagnosis and
treatment of invasive fungal infections. Because intensive
diagnostic monitoring is commonly precluded in the outpa-
tient setting, antifungal prophylaxis, with, for example, posa-
conazole, may be a feasible approach for high-risk patients.
Exposing large patient groups to antifungal drugs such as the
azoles may have negative consequences with regard to the
development of resistance, toxicity or drug interactions.
However, increased insight into the role of genetic and bio-
logical host factors concerning the risk of developing invasive
fungal infection may help us to target only those patients
who are at greatest risk. Recognition of genetic or biological
factors is therefore needed in the pre-selection period in the
case of transplant recipients or early in the course of therapy
because the impact of these factors has been shown to be
signiﬁcant [51]. Efforts directed towards discovery and
validation of new strategies that incorporate these factors
should be undertaken.
Treatment-related Factors Predisposing to
Invasive Fungal Infections
Among immunocompromised patients, invasive mould infec-
tions occur most often in the setting of haematological
diseases. This is especially related to aggressive treatment
regimens, resulting in prolonged periods of cytopenia and
the use of high doses of corticosteroids. Also in patients
who receive less myeloablative regimens, such as the novel
purine antagonists and antibody therapies, the risk of
developing invasive fungal infection remains signiﬁcant
[52,53].
Patients who have survived invasive aspergillosis have an
increased risk of the fungal disease relapsing during subse-
quent immunosuppressive treatment episodes. Martino et al.
[54] performed a study in which a comparison was made
between reduced, as opposed to conventional (i.e. intensive),
conditioning regimens in patients with proven previous
invasive mould infection. Despite the retrospective design of
this study, signiﬁcant differences in relapse rates were
observed. The augmentation of the risk of a relapse of inva-
sive aspergillosis was noted, especially during the ﬁrst
30 days after a transplantation [54]. In addition, cytomegalo-
virus (CMV) disease, cord blood or bone marrow stem cells
as a source of the transplant, and severity of GvHD were
found to be important factors in relation to the risk of
relapse of invasive aspergillosis. Throughout the entire treat-
ment period, the status of the underlying disease, the dura-
tion of neutropenia, as well as duration of previous antifungal
therapy (i.e. from start of therapy until the day of transplan-
tation), determined the likelihood of the reactivation of
invasive aspergillosis. The latter is of importance because it
suggests that a certain total dose and duration of antifungal
therapy is needed for an invasive fungal infection to be under
control. In this study, voriconazole was found to show a
trend towards an effective prophylaxis against relapse of
invasive fungal infection, especially as a result of moulds.
When the results of this retrospective study were set in a
risk assessment model (except for the intensity of condition-
ing), this model proved to accurately predict the probability
of invasive aspergillosis relapse. Together with the aforemen-
tioned validated diagnostic techniques, such as galactomannan
antigen testing, this model should be investigated further.
Other, time-dependent, biological host factors were evalu-
ated for their role in the risk of acquisition of invasive mould
infection in HSCT-recipients by Garcia-Vidal et al. [51].
Notably, the majority of invasive mould infections (of which
87% were invasive aspergillosis) occurred late after HSCT
(i.e. more than 40 days after transplantation). Factors predis-
TABLE 2. Host-related factors that inﬂuence the suscepti-
bility to invasive fungal infection, and possible underlying
mechanisms
Genetic factors Mechanism
Defective oxidant production
within PMN Aggregates
Impaired neutrophil recruitment
SNPs in IL-10 promoter gene High IL-10 levels with consequently
impaired cytokine production
TNFa receptor 2 gene promoter
disturbance
Impaired (mainly too low) TNFa
levels with consequently impaired
control of infection
SNPs in Toll-like receptors 4
haplotype S4. Polymorphism
in Toll-like receptors 1 and 6
Impaired immune signal at time of
infection. Defect in production of
inﬂammatory cytokines
Polymorphism in the plasminogen
gene
Impaired immune response at time
of infection
IL, interleukin; PMN, polymorphonuclear neutrophil; SNP, single nucleotide
polymorphism; TNF, tumour necrosis factor.
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posing to early occurrence of the infection were the exis-
tence of underlying disease and were related to the type of
transplant, such as unrelated or mismatched HSCT along
with conditioning with ATG. An increased incidence of inva-
sive mould infection during the early phase of immune
reconstitution was associated with hyperglycaemia, lymp-
hopenia and the number of blood transfusions as marker for
iron overload. Interestingly, the number of blood transfu-
sions was associated with a higher incidence of mould infec-
tion during the early as well as late phase, but ferritin, a
more accurate marker of iron overload, was not found to be
associated with increased proneness to invasive mould infec-
tion. For the period beyond 40 days after transplantation, as
in other studies, the severity of GvHD, the presence of
CMV disease, the high number of transfusions, and receipt of
high doses of corticosteroids determined the risk of an inva-
sive mould infection [52,55,56].
The Impact of Novel Treatment Strategies
Used for Haematological Diseases
Concerning the novel therapies, alemtuzumab, an antibody
directed against T-cells, was associated with an increased
incidence of opportunistic infections. In the ﬁrst cohorts of
alemtuzumab-treated patients, invasive aspergillosis appeared
to be the most frequent opportunistic infection [53]. This
was seen both in patients treated solely with alemtuzumab
as well as in those given alemtuzumab as part of the condi-
tioning regimen of an allo-HSCT. Subsequent reports
suggested that especially patients treated with alemtuzumab,
for rejection of the transplant or as salvage therapy, were at
highest risk of an opportunistic fungal infection [52,57]. Of
note, in most HSCT-recipients treated with alemtuzumab,
invasive fungal infection tended to occur relatively late (i.e.
more than 1 year after transplantation). Similar results were
reported with ﬂudarabine, a purine antagonist, which allows
for a less myeloablative conditioning regimen. Despite the
possible advantage of a less intensive conditioning, fungal
infections, together with CMV disease, remained signiﬁcant
clinical problems [12,58].
Although less myeloablative conditioning in HSCT is pre-
ferred because it may diminish the risk of early infectious
complications, including invasive fungal diseases, one should
be aware that, even long after these procedures, the cellular
immunity remains impaired, with a consequent continued
risk of invasive fungal infection [12].
Conclusions
Basic research and clinical trials have increased our under-
standing of the interplay between the fungus and the host
(Fig. 1). More accurate diagnostic tools and effective antifun-
gal drugs have improved the prognosis for patients at high
risk of invasive fungal diseases. However, our efforts are
threatened by resistance development and shifts in the epi-
demiology of fungal pathogens towards less common moulds.
It would be unrealistic to expect that, in the near future, we
will overcome the morbidity and mortality associated with
FIG. 1. Interplay among factors related to the
host, the fungus and antifungal drugs.
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invasive fungal infections. By contrast, every effort needs to
be made to continue improving the survival of patients who
suffer from fungal complications of immunosuppressive thera-
pies.
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